Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026

A securities class action has been filed against ARS Pharmaceuticals on behalf of investors who bought shares between March 9 and June 24, 2026, following allegations related to disclosures on neffy payer access. ARS said no new commercial formulary additions or coverage decisions for neffy were issued in the July 1 coverage cycle; its shares subsequently fell $2.52, or 23.9%, to $8.02 on June 25. Investors have until October 5, 2026 to seek appointment as lead plaintiff.

Analysis

The litigation notice is not independently investable; the underlying issue is whether neffy's commercial reimbursement ramp is materially behind the revenue trajectory embedded in sell-side models. Delayed formulary wins can create a nonlinear problem for SPRY: prescription demand may be present, but out-of-pocket friction depresses fills, forcing greater copay support and distribution spending while revenue recognition lags. That combination raises the probability of a cash-burn revision and dilutive financing risk over the next 2-4 quarters if broad coverage does not arrive.

The more relevant competitive read-through is favorable for incumbent emergency-allergy products, including Viatris (VTRS) and Teva (TEVA), whose established epinephrine auto-injector access is protected when a novel delivery format cannot convert payer discussions into covered lives. However, the post-disclosure equity decline likely already reflects a substantial portion of the near-term access disappointment; initiating a fresh outright SPRY short solely on plaintiff-law-firm headlines offers poor asymmetry. The decisive 1-3 month catalyst is evidence of covered-life additions and paid-prescription conversion, while the 6-18 month issue is whether payer access arrives before SPRY must reset commercial-spend assumptions or raise capital.

Consensus may underappreciate that a favorable formulary announcement is not equivalent to commercial success: tier placement, prior authorization, step edits, and patient copay remain the variables that determine net revenue. Conversely, bears may be over-extrapolating one coverage cycle; a cluster of regional or national wins could rapidly improve the narrative because the product's differentiated route of administration remains clinically and commercially relevant. Falsify the bearish operating thesis if subsequent disclosures show broad commercial coverage plus accelerating filled prescriptions without a corresponding increase in patient-assistance expense; validate it if management lowers net-sales guidance, increases cash-use guidance, or reports weak conversion despite added covered lives.

Key Decisions for Investors

• Do not trade SPRY on the lawsuit announcement itself; treat the October 5 lead-plaintiff deadline as legally relevant but not a fundamental catalyst. Reassess only on the next payer-access update, earnings release, or a financing filing.
• Maintain a bearish SPRY watch position only if data show another missed formulary cycle or management cuts net-sales/cash-runway expectations; use a defined-risk put spread 3-6 months out rather than an outright short after the sharp decline. Exit if broad coverage wins are accompanied by improving paid-fill metrics.
• Consider a small 3-6 month pair: long VTRS versus short SPRY, sized conservatively, to isolate reimbursement-execution risk from broader biotech beta. The thesis is invalidated by SPRY demonstrating rapid covered-life expansion and favorable net-price realization, not merely an announced payer discussion.
• For long-biotech books, require confirmation of cash runway through at least the next major coverage decision cycle before adding SPRY exposure; absent that disclosure, model a higher probability of equity dilution and avoid averaging down.